Kodiak Sciences’ (KOD) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Kodiak Sciences (NASDAQ:KOD) in a report released on Friday,Benzinga reports. The firm currently has a $3.00 price objective on the stock.

Kodiak Sciences Trading Up 2.4 %

NASDAQ KOD opened at $5.66 on Friday. Kodiak Sciences has a 12 month low of $2.18 and a 12 month high of $7.77. The firm has a market capitalization of $297.83 million, a PE ratio of -1.55 and a beta of 2.26. The business’s 50-day moving average price is $3.42 and its two-hundred day moving average price is $3.06.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of Kodiak Sciences during the third quarter worth $33,000. Meeder Asset Management Inc. acquired a new stake in Kodiak Sciences during the 2nd quarter worth about $36,000. Sanctuary Advisors LLC bought a new position in shares of Kodiak Sciences in the 2nd quarter worth about $36,000. LJI Wealth Management LLC lifted its stake in shares of Kodiak Sciences by 21.3% in the 3rd quarter. LJI Wealth Management LLC now owns 17,100 shares of the company’s stock valued at $45,000 after purchasing an additional 3,000 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of Kodiak Sciences in the 1st quarter valued at about $50,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.